Articles tagged "Immunosuppression"

2019 American Transplant Congress
Sirolimus in Geriatric Kidney Transplantation: Modification of Outcomes by Pre-Transplant History of Malignancy or Cardiovascular Disease
H. Ibrahim¹, C. Chen², K. Alquadan³, X. Wen⁴, K. L. Womer³, A. H. Santos Jr¹
¹College of Medicine, Div. of Nephrology, Hypertension & Renal Transplantation, Univ. of Florida, Gainesville, FL, ²College of Pharmacy, Univ. of Florida, Gainesville, FL, ³College of Medicine, Div. of Nephrology, Hypertension & Renal Transplantation, Univ. of Florida, Gainesville, FL, ⁴College of Pharmacy, Univ. of Rhode Island, Kingston, RI
*Purpose: We analyzed the outcomes associated with sirolimus (SRL)-regimens in geriatric (>/=65-year-old) kidney transplant recipients (KTRs).*Methods: Using 2000-2016 Scientific Registry of Transplant Recipients data, Cox…
2019 American Transplant Congress
The Use of mTOR Inhibitors Prevents Acute Cellular Rejection in Kidney Transplantation on Belatacept Therapy
J. Shoji, J. C. Leung, Q. Tang, J. P. Roberts, F. Vincenti
University of California San Francisco, San Francisco, CA
*Purpose: Belatacept is a costimulatory blocker that is used as de novo maintenance immunosuppression in kidney transplantation to avoid toxic effects of calcineurin inhibitors and…
2019 American Transplant Congress
Conversion from Calcineurin Inhibitors to Belatacept in Kidney Recipients with Donor-Specific Anti-HLA Antibodies and Calcineurin Inhibitor Nephrotoxicity Decreases the Pathogenicity of Donor-Specific Anti-HLA Antibodies
K. Louis¹, D. Viglietti¹, D. Pievani¹, O. Aubert¹, D. Glotz¹, C. Legendre¹, A. Zeevi², A. Loupy¹, C. Lefaucheur¹
¹Paris Translational Research Center for Organ Transplantation, Paris, France, ²University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: Switching from CNI- to Belatacept-based regimen has been associated with improved graft function in low-immunologic risk kidney recipients. We investigated the efficacy and safety…
2019 American Transplant Congress
LCP-Tacrolimus (LCPT; Envarsus XR) Dosing Considerations in De Novo Kidney Transplant Recipients
D. Cibrik¹, P. West-Thielke², S. J. Patel³, D. R. Stevens⁴, U. Meier-Kriesche⁴
¹University of Kansas Medical Center, Kansas City, KS, ²University of Illinois Hospital and Health Sciences System, Chicago, Chicago, IL, ³Veloxis Pharmaceuticals, Cary, NC, ⁴Veloxis Pharmaceuticals Inc., Cary, NC
*Purpose: Different initial dosing strategies were studied in Phase II/Phase III trials evaluating the pharmacokinetics, safety, and efficacy of LCPT in de novo kidney transplantation.…
2019 American Transplant Congress
Utility of AlloSure Monitoring in Simultaneous Kidney and Pancreas Recipients
J. A. Klein, A. Gupta, P. Budhiraja, D. Cibrik
Nephrology, University of Kansas Medical Center, Kansas City, KS
*Purpose: Determine utility and efficacy of donor-derived cell free DNA (dd-cfDNA) monitoring in simultaneous kidney and pancreas (SPK) recipients compared to kidney transplant alone (KTA).…
2019 American Transplant Congress
Clinical Impact of Race and Timing of Acute Rejection on Recipients of Kidney Transplant on Early Steroid Withdrawal Protocol
O. Adebiyi, S. Yaqub, W. Goggins, D. Mishler, T. Taber, A. Sharfuddin
Indiana University, Indianapolis, IN
*Purpose: There has been conflicting reports on the impacts of the timing of acute rejection (AR) (early vs late) on the overall outcome of a…
2019 American Transplant Congress
Long-Term Survival Analysis of Kidney Transplant Recipients Receiving Mizoribine as a Maintenance Immunosuppressant
J. Kim¹, D. Lee¹, J. Oh¹, J. Lee¹, H. Kim¹, Y. Son²
¹Nephrology, Bongseng hospital, Busan, Korea, Republic of, ²Nephrology, Donga University hospital, Busan, Korea, Republic of
*Purpose: It has proved effective as a treatment for lupus nephritis, rheumatoid arthritis, and nephrotic syndrome, after mizoribine was introduced as an immunosuppressive agent to…
2019 American Transplant Congress
Combined Antithymocyte Globulin (ATG) and Rituximab (RTX) Induction in African American (AA) Kidney Transplant Recipients
S. J. Patel, S. Kuten, C. Pham, R. Knight, M. Hobeika, D. Nguyen, E. Graviss, S. Yi, T. Eagar, A. Gaber
Methodist Hospital, Houston, TX
*Purpose: We have previously shown that despite the use of T cell-depleting antibody induction, AA kidney transplant recipients (KTR) remain at high risk of rejection…
2019 American Transplant Congress
Transplantation Alone Induces Myeloid-Derived Suppressor Cells Which Can Suppress T Cell Responses
Y. Lee, T. Zhang, J. S. Bromberg, J. R. Scalea
University of Maryland, Baltimore, MD
*Purpose: Myeloid-derived suppressor cells (MDSC) are a naturally occurring, heterogeneous population of highly immunosuppressive CD11b+GR-1+ cells that expand in response to inflammatory conditions. MDSCs develop…
2019 American Transplant Congress
A Cost Saving Quality Improvement Project in Solid Organ Transplant Population Following Tacrolimus Switch from Prograf® to Adoport® Immunosuppression – A Single Centre Experience
L. Mulreid, M. Vincent, L. Laycock, A. Summers, S. Bhutani
Manchester Royal Infirmary, Manchester, United Kingdom
*Purpose: Tacrolimus is widely used immunosuppressive drugs in transplantation. The use of generic medications is cost saving and economically advantageous for the National Health Services…